Actavis, a global, integrated specialty pharmaceutical company, and Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, have received a request for additional information from the Federal Trade Commission (FTC) in connection with Actavis' pending acquisition of Forest.  The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act).

The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Actavis and Forest have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC.  Actavis and Forest intend to cooperate fully with the FTC and they continue to expect the transaction to close in mid-year 2014.